SBIR/STTR Phase I: Targeted Drug Delivery with Magnetic Nanoparticles

这个小型企业技术转移研究(STTR)第一阶段项目将开发一种方法，通过在同一种药物中结合治疗和成像来改进癌症的诊断和治疗。具体地说，本研究建议将聚乙二醇包覆的磁性纳米胶束结合到肿瘤靶向治疗剂(阿霉素包裹的温敏脂质体和水凝胶)上，并将其螯合到Tc-99m上进行成像。给药后，药物将在外部磁引导下集中在作用部位，通过伽马相机成像验证，并通过热疗释放到肿瘤。与该复合体结合的肿瘤特异性标记物将改善药物向肿瘤的转运。一旦进入肿瘤内部，治疗剂就会被释放出来杀死癌细胞。这个第一阶段项目的具体目标是：(1)开发必要的化学和偶联，(2)使用体外流动模型来检测络合物的磁化率，(3)在体外细胞培养模型中进行测试。该项目的商业应用是在癌症的治疗中。建议的方法将通过确保药物到达靶组织同时将非靶组织摄取降至最低，从而提高癌症治疗的疗效。

This Small Business Technology Transfer Research (STTR) Phase I Project will develop a methodology for improved diagnosis and treatment of cancer by combining therapy and imaging in the same drug. Specifically, this study proposes to bind polyethylene glycol (PEG) coated magnetic nanopheres to a cancer targeting therapeutic agent (doxorubicin encapsulated temperature sensitive liposomes and hydrogels) and chelated to Tc-99m for imaging. After administration, the drug will be concentrated at the site of action by external magnetic guidance, verified by gamma camera imaging and released to the tumor using herperthermia treatment. A tumor specific marker bound to the complex will improve drug transport into the tumor. Once inside the tumor, therapeutic agents will be released to kill the cancer cells. Specific Goals of this Phase I Project are: (1) to develop the necessary chemistry and conjugation, (2) to examine the magnetic susceptibility of the complex using an in vitro flow model, and (3) to conduct tests in an in vitro cell culture model.The commercial applications of this project are in the treatment of cancer. The proposed method will enhance the efficacy of cancer treatment by ensuring that the drug reaches the target tissue while minimizing non-target tissue uptake.